资料来源:FDA网站发布时间:2009.11.09美国食品药品监督管理局批准可注射型药物Istodax(romidepsin)用于治疗罕见癌症——皮肤T细胞淋巴癌(CTCL)。CTCL是与一种名叫T淋巴细胞的抗感染的白细胞有关的生长缓慢的癌症。大部分病人起初皮肤干燥,有红疹,进而严重瘙痒。皮肤会长出溃疡性瘤,引起感染。在一些案例中,CTCL会扩散到血液、淋巴管或其他内脏中。在美国,每年会新增 Source: FDA Web site Release Date: 2009.11.09 FDA Approves Istodax (romidepsin), an Injectable, for the Treatment of Rare Skin Cancer T-Cell Lymphoma (CTCL). CTCL is a slow-growing cancer associated with an anti-infective leukocyte called T-lymphocyte. Most patients initially have dry skin, rashes and severe itching. The skin will grow ulcerated tumors, causing infection. In some cases, CTCL can spread to the blood, lymphatic vessels or other organs. In the United States, every year will be added